First- or second- generation EGFR-TKI was still the first-line choice for treatment of NSCLC patients with EGFR mutation and re-biopsy remained important in detecting the T790M mutation after the failure of first- and second-generation EGFR-TKI treatment in Asian countries. Here, EGFR is linked to non-small cell lung carcinoma.